Cargando…

Antileishmanial activity of 5-nitroindazole derivatives

BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollineda-Diogo, Niurka, Chaviano-Montes de Oca, Claudia Sissely, Sifontes-Rodríguez, Sergio, Espinosa-Buitrago, Teresa, Monzote-Fidalgo, Lianet, Meneses-Marcel, Alfredo, Morales-Helguera, Aliuska, Perez-Castillo, Yunierkis, Arán-Redó, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617274/
https://www.ncbi.nlm.nih.gov/pubmed/37915499
http://dx.doi.org/10.1177/20499361231208294
_version_ 1785129574433030144
author Mollineda-Diogo, Niurka
Chaviano-Montes de Oca, Claudia Sissely
Sifontes-Rodríguez, Sergio
Espinosa-Buitrago, Teresa
Monzote-Fidalgo, Lianet
Meneses-Marcel, Alfredo
Morales-Helguera, Aliuska
Perez-Castillo, Yunierkis
Arán-Redó, Vicente
author_facet Mollineda-Diogo, Niurka
Chaviano-Montes de Oca, Claudia Sissely
Sifontes-Rodríguez, Sergio
Espinosa-Buitrago, Teresa
Monzote-Fidalgo, Lianet
Meneses-Marcel, Alfredo
Morales-Helguera, Aliuska
Perez-Castillo, Yunierkis
Arán-Redó, Vicente
author_sort Mollineda-Diogo, Niurka
collection PubMed
description BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity against Trichomonas vaginalis and Trypanosoma cruzi. On that basis, 20 indazole derivatives were tested in vitro against Leishmania amazonensis. OBJECTIVE: To evaluate the in vitro activity of twenty 2-benzyl-5-nitroindazolin-3-one derivatives against L. amazonensis. DESIGN: For the selection of promising compounds, it is necessary to evaluate the indicators for in vitro activity. For this aim, a battery of studies for antileishmanial activity and cytotoxicity were implemented. These results enabled the determination of the substituents in the indazole derivatives responsible for activity and selectivity, through the analysis of the structure–activity relationship (SAR). METHODS: In vitro cytotoxicity against mouse peritoneal macrophages and growth inhibitory activity in promastigotes were evaluated for 20 compounds. Compounds that showed adequate selectivity were tested against intracellular amastigotes. The SAR from the results in promastigotes was represented using the SARANEA software. RESULTS: Eight compounds showed selectivity index >10% and 50% inhibitory concentration <1 µM against the promastigote stage. Against intracellular amastigotes, four were as active as Amphotericin B. The best results were obtained for 2-(benzyl-2,3-dihydro-5-nitro-3-oxoindazol-1-yl) ethyl acetate, with 50% inhibitory concentration of 0.46 ± 0.01 µM against amastigotes and a selectivity index of 875. The SAR study showed the positive effect on the selectivity of the hydrophilic fragments substituted in position 1 of 2-benzyl-5- nitroindazolin-3-one, which played a key role in improving the selectivity profile of this series of compounds. CONCLUSION: 2-bencyl-5-nitroindazolin-3-one derivatives showed selective and potent in vitro activity, supporting further investigations on this family of compounds as potential antileishmanial hits.
format Online
Article
Text
id pubmed-10617274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106172742023-11-01 Antileishmanial activity of 5-nitroindazole derivatives Mollineda-Diogo, Niurka Chaviano-Montes de Oca, Claudia Sissely Sifontes-Rodríguez, Sergio Espinosa-Buitrago, Teresa Monzote-Fidalgo, Lianet Meneses-Marcel, Alfredo Morales-Helguera, Aliuska Perez-Castillo, Yunierkis Arán-Redó, Vicente Ther Adv Infect Dis Original Research BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity against Trichomonas vaginalis and Trypanosoma cruzi. On that basis, 20 indazole derivatives were tested in vitro against Leishmania amazonensis. OBJECTIVE: To evaluate the in vitro activity of twenty 2-benzyl-5-nitroindazolin-3-one derivatives against L. amazonensis. DESIGN: For the selection of promising compounds, it is necessary to evaluate the indicators for in vitro activity. For this aim, a battery of studies for antileishmanial activity and cytotoxicity were implemented. These results enabled the determination of the substituents in the indazole derivatives responsible for activity and selectivity, through the analysis of the structure–activity relationship (SAR). METHODS: In vitro cytotoxicity against mouse peritoneal macrophages and growth inhibitory activity in promastigotes were evaluated for 20 compounds. Compounds that showed adequate selectivity were tested against intracellular amastigotes. The SAR from the results in promastigotes was represented using the SARANEA software. RESULTS: Eight compounds showed selectivity index >10% and 50% inhibitory concentration <1 µM against the promastigote stage. Against intracellular amastigotes, four were as active as Amphotericin B. The best results were obtained for 2-(benzyl-2,3-dihydro-5-nitro-3-oxoindazol-1-yl) ethyl acetate, with 50% inhibitory concentration of 0.46 ± 0.01 µM against amastigotes and a selectivity index of 875. The SAR study showed the positive effect on the selectivity of the hydrophilic fragments substituted in position 1 of 2-benzyl-5- nitroindazolin-3-one, which played a key role in improving the selectivity profile of this series of compounds. CONCLUSION: 2-bencyl-5-nitroindazolin-3-one derivatives showed selective and potent in vitro activity, supporting further investigations on this family of compounds as potential antileishmanial hits. SAGE Publications 2023-10-30 /pmc/articles/PMC10617274/ /pubmed/37915499 http://dx.doi.org/10.1177/20499361231208294 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Mollineda-Diogo, Niurka
Chaviano-Montes de Oca, Claudia Sissely
Sifontes-Rodríguez, Sergio
Espinosa-Buitrago, Teresa
Monzote-Fidalgo, Lianet
Meneses-Marcel, Alfredo
Morales-Helguera, Aliuska
Perez-Castillo, Yunierkis
Arán-Redó, Vicente
Antileishmanial activity of 5-nitroindazole derivatives
title Antileishmanial activity of 5-nitroindazole derivatives
title_full Antileishmanial activity of 5-nitroindazole derivatives
title_fullStr Antileishmanial activity of 5-nitroindazole derivatives
title_full_unstemmed Antileishmanial activity of 5-nitroindazole derivatives
title_short Antileishmanial activity of 5-nitroindazole derivatives
title_sort antileishmanial activity of 5-nitroindazole derivatives
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617274/
https://www.ncbi.nlm.nih.gov/pubmed/37915499
http://dx.doi.org/10.1177/20499361231208294
work_keys_str_mv AT mollinedadiogoniurka antileishmanialactivityof5nitroindazolederivatives
AT chavianomontesdeocaclaudiasissely antileishmanialactivityof5nitroindazolederivatives
AT sifontesrodriguezsergio antileishmanialactivityof5nitroindazolederivatives
AT espinosabuitragoteresa antileishmanialactivityof5nitroindazolederivatives
AT monzotefidalgolianet antileishmanialactivityof5nitroindazolederivatives
AT menesesmarcelalfredo antileishmanialactivityof5nitroindazolederivatives
AT moraleshelgueraaliuska antileishmanialactivityof5nitroindazolederivatives
AT perezcastilloyunierkis antileishmanialactivityof5nitroindazolederivatives
AT aranredovicente antileishmanialactivityof5nitroindazolederivatives